Identification of the genetic factors that underlie stimulant responsiveness in animal models has significant implications for better understanding and treating stimulant addiction in humans. F 2 progeny derived from parental rat strains F344/NHsd and LEW/NHsd, which differ in responses to drugs of abuse, were used in quantitative trait locus (QTL) analyses to identify genomic regions associated with amphetamine-induced locomotion (AIL) and G-protein levels in the nucleus accumbens (NAc). The most robust QTLs were observed on chromosome 3 (maximal log ratio statistic score (LRS max ) ¼ 21.3) for AIL and on chromosome 2 (LRS max ¼ 22.0) for Ga i3 . A 'suggestive' QTL (LRS max ¼ 12.5) was observed for AIL in a region of chromosome 2 that overlaps with the Ga i3 QTL. Noveltyinduced locomotion (NIL) showed different QTL patterns from AIL, with the most robust QTL on chromosome 13 (LRS max ¼ 12.2). Specific unique and overlapping genomic regions influence AIL, NIL, and inhibitory G-protein levels in the NAc. These findings suggest that common genetic mechanisms influence certain biochemical and behavioral aspects of stimulant responsiveness.
INTRODUCTION
Differences in individual responses to stimulants exist in humans and other species. Some exposed individuals become dependent on amphetamine, methamphetamine, or cocaine, while others do not (Barr et al, 2006; Sofuoglu and Kosten, 2006) . Genetic influences on psychiatric disorders associated with stimulant usage are also significant, with the genetic contributions to drug dependence (including to stimulants) estimated at 30-60% (Tsuang et al, 1998) . Divergent responses to stimulants are also important in the clinical arena, in which some individuals with attention-deficit hyperactivity disorder are treated effectively with amphetamine or methylphenidate (Biederman et al, 2004) . Cocaine dependence risk loci have been mapped in humans via genetic linkage (Gelernter et al, 2005) ; animal studies, however, provide the opportunity to identify risk loci for specific traits associated with pharmacological responses and other phenotypes that cannot be readily ascertained in human subjects.
Amphetamine-induced locomotion (AIL) is a well-studied phenomenon in animal models of psychiatric disorders, including stimulant addiction and psychoses (Blackburn and Szumlinski, 1997; Ikemoto and Witkin, 2003; Rajakumar et al, 2005) . AIL, regarded as a measure of mesolimbic dopamine function (Dellu-Hagedorn, 2005) , is mediated via dopaminergic transmission in the nucleus accumbens (NAc) (Kim and Vezina, 1998; Chausmer and Ettenberg, 1999; Millan et al, 1999; Ikemoto and Witkin, 2003) . AIL differs from other types of locomotion, such as noveltyinduced locomotion (NIL), which has been associated with stress responses. A complex relationship exists between drug-induced behaviors and novelty responses in rodents (Hiroi and Agatsuma, 2005; Agatsuma et al, 2006) . AIL is differentially regulated in rats with high or low levels of spontaneous exploratory behavior (Corda et al, 2005; Alttoa et al, 2007) . While AIL and NIL correlate with one another in some studies, genetically distinct animal strains show differences in AIL and NIL, and these animals provide an opportunity for identifying genetic factors influencing stimulant responsiveness (Brodkin et al, 1998; Marley et al, 1998; Stohr et al, 1998; Conversi et al, 2006) . For example, Fisher (F344/NHsd) as compared with Lewis (LEW/NHsd) rats show more robust AIL and roughly equivalent NIL (Brodkin et al, 1998; Stohr et al, 1998) .
F344/NHsd and LEW/NHsd (referred to hereafter as F344 and LEW, respectively) rat lines have been used as models for multiple psychiatric disorders including addiction (Nestler et al, 1996; Kosten and Ambrosio, 2002) , schizophrenia (Lipska and Weinberger, 1996) , and depression (Lahmame et al, 1997) . Previously, we reported differences in AIL and related phenotypes in these strains and their F2 progeny that were generated in preparation for quantitative trait locus (QTL) analysis (Brodkin et al, 1998) . Multiple biochemical phenotypes related to striatal dopamine function, and implicated in stimulant addiction, were measured by western blotting specifically in the NAc, including inhibitory G-protein subunits (Ga i1,2 and Ga i3 ), the dopamine transporter (DAT), the transcription factor DFosB, and the protein phosphatase inhibitor DARPP-32. Among the phenotypes investigated, levels of Ga i subunits appeared particularly promising for further study in QTL analyses (Brodkin et al, 1998) . QTL analysis has been used previously to identify genomic regions contributing to a variety of quantitative traits, for example, stress responsiveness, alcohol or morphine consumption, aggressive behaviors, and behavioral reactivity and emotionality (Moisan et al, 1996; Remmers et al, 1996; Bice et al, 1998; Ramos et al, 1999; Brodkin et al, 2002; Potenza et al, 2004; Ferraro et al, 2005) . QTL analysis appears particularly applicable to the study of phenotypes related to psychiatric disorders, given its ability to identify genomic contributions to phenotypes determined by multiple genes. However, the genomic regions identified are usually large and contain multiple candidate genes, and additional investigation is typically required to identify specific genes.
Previously, we used QTL analysis to identify regions on chromosomes 4 and 10, which contribute to differences in peak corticosterone levels in F344 and LEW rats (Potenza et al, 2004) . Here, we use a similar approach to investigate genetic contributions to AIL and levels of Ga i1,2 and Ga i3 in the NAc, using NIL as a behavioral control condition for AIL. We hypothesized that (1) we would identify genomic regions contributing to AIL, NIL, Ga i1,2 levels, and Ga i3 levels, (2) genomic regions contributing to AIL would be distinct from those contributing to NIL, and (3) genomic regions contributing to AIL would partially overlap with those contributing to levels of Ga i1,2 and Ga i3 in the NAc.
MATERIALS AND METHODS

Animal Procedures
The animal care and use committee at Yale University approved the study. The research was performed in strict accordance with the NIH Guide for the Care and Use of Laboratory Animals. F344 and LEW rats were maintained and characterized as described previously (Brodkin et al, 1998; Potenza et al, 2004) . F344 and LEW rats were obtained from Harlan Sprague Dawley (Indianapolis, IN) at 35-45 days of age. F 1 progeny were generated by both F344 (female) Â LEW (male) and LEW (female) Â F344 (male) crosses and F 2 intercross progeny were derived from mating of both (F344 Â LEW)F 1 Â (F344 Â LEW)F 1 and (LEW Â F344)F 1 Â (LEW Â F344)F 1 pairs. F 2 progeny were weaned at 21 days of age. Animals were housed in groups of 2-4 with food (Purina chow) and tap water ad libitum in a temperature-controlled colony with a 12-h light/dark cycle (lights on at 0700 hours). Only males were included in this study, to limit variation in measures associated with the estrus cycle in females, and given known sex differences in F344 and LEW rats in AIL and NIL (Stohr et al, 1998) .
Locomotor Activity Measures
Rats were assessed for locomotor activity between 0800 and 1000 hours and between the ages of 50 and 60 days using a concentric circular device as described previously (Brodkin et al, 1998) . Activity was recorded for 60 min. Data for the first 10 min of activity in the novel environment were used to assess NIL, as prior studies showed that differences among rats in NIL were most pronounced during this time (Brodkin et al, 1998) . Immediately following the 60 min test period, animals received injections of DL-amphetamine hemisulfate (2.0 mg/kg, s.c.), and locomotor activity was measured for an additional 60 min. Amphetamine was supplied by the National Institute on Drug Abuse (Baltimore, MD), made in isotonic saline and administered in a volume of 1 ml/kg. AIL data were calculated as cumulative activity over the 60-min test period.
Serum Levels of Amphetamine
F344 and LEW rats were given amphetamine (2 mg/kg, i.p.) and trunk blood was obtained 40 min later, at the peak of behavioral effects of amphetamine. Samples were centrifuged for 10 min at 3000g and the serum was removed and stored at À201C until analysis. Before analysis, amphetamine-d3 (50 ng/ml) was added to each sample as an internal standard. Serum amphetamine levels were detected using a Micromass Ultima liquid chromatography/tandem mass spectrometry system (Waters Corp., Milford, MA) in positive ion mode and a BDS-C18 column (ThermoFischer Scientific Inc., West Palm Beach, FL) with a 0.8 ml/min flow rate as previously described (Hendrickson et al, 2004) . Mobile phase was 20% acetonitrile, 0.05% acetic acid, and 5 mM ammonium acetate. Amphetamine signals were quantified by comparison of multiple reaction monitoring signals to the internal standard.
G Protein Measures
Five to eight days after behavioral testing, animals were killed by decapitation between 1500 and 1700 hours as described previously (Brodkin et al, 1998) . This was performed in a separate area from animal housing, with each animal retrieved individually from the housing area, and with glove changing between animals to minimize possible stress-related alterations in mesolimbic functioning. Brains were removed rapidly and cooled in ice-cold physiological buffer (Brodkin et al, 1998) . The NAc samples were obtained from 1-mm-thick coronal cross-sections using a 12-gauge syringe needle and were stored at À701C until western blotting was performed as reported previously (Brodkin et al, 1998) .
DNA Extraction, Purification, Amplification, and Analysis
As described previously (Potenza et al, 2004) , genomic DNA was obtained from frozen liver tissue of F344 and LEW parental animals and F 2 progeny via alkaline lysis and column purification strategy (Qiagen; www.qiagen.com). DNA quality was assessed by agarose gel electrophoresis. DNA amplification was performed using the polymerase chain reaction and primers obtained from Research Genetics (www.resgen.com), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (Bethesda, MD) (Remmers et al, 1996) , or Applied Biosystems Incorporated (ABI; www.appliedbiosystems.com). DNA analysis was performed via size fractionation, either via agarose gel electrophoresis and ethidium bromide visualization, or acrylamide gel electrophoresis and fluorescence detection using an ABI 377 semiautomated sequencer. Data from these gels were independently read by two individuals and double-entered prior to analysis.
QTL Analysis
QTL analysis was performed as described previously (Remmers et al, 1996; Potenza et al, 2004) . Sample sizes were based on power analyses and prior studies that successfully identified QTLs in rats (Remmers et al, 1996) . Out of 298 F 2 progeny, including those with phenotypic extremes for AIL, NIL, Ga i1,2 levels, and Ga i3 levels (top and bottom 5-15%), 188 were analyzed at 178 genetic loci distributed across the rat autosomes (average (SD) spacing of 8.65 (4.62) cM). We investigated power for the QTL analysis using the method of revolving power (Darvasi and Soller, 1997) , which was calculated under the assumption of an infinite number of markers and was found to be similar to the 95% confidence interval (CI) of QTL map location using moderate marker spacing, for example, 10-20 cM. Our analysis showed that with a sample size of 188, the 95% CI is 20 cM for a standardized dominant effect of d ¼ 0.63. The average spacing (8.65 cM) of the 178 genetic loci used in this study is substantially smaller than 20 cM, and with denser marker spacing, smaller effect sizes can be detected. Based on these analyses, we have a good coverage of marker variation and adequate power to detect QTL of magnitudes of d ¼ 0.63 or less. Data were analyzed as described previously with MAP-MAKER/EXP and MAPMAKER/QTL (Remmers et al, 1996) and MapManager QT (Manly and Olson, 1999) . Data presented are from analyses using MapManager QT. The likelihood ratio statistic (LRS) score, a value that is 4.6 times the lod score value, is used to report the magnitude of the QTLs, as has been done previously when reporting results from analyses using MapManager QT (McBrearty et al, 1998; Hahn et al, 2004; Potenza et al, 2004) . 'Suggestive significance' and 'genomewide significance' thresholds were those recommended by Lander and Kruglyak (1995) , using LRS scores of 9.9 and 15.2 for 'suggestive' and (genomewide) 'significant' QTLs, respectively. Marker map locations from an SHRSPxBN genetic map as described in the rat genome database (www.rgd.mcw.edu/GENOMESCANNER) were used in the QTL analyses, with study data-derived distances used for six markers (D1Arb8, D1Arb11, D1Arb25, D4Arb17, D12Arb8, and D20Mgh1) not available from the map. Exploration of candidate genes in the vicinities of identified QTL and identification of corresponding regions of human and mouse genomes were performed using the NCBI Map Viewer (http://www.ncbi. nlm.nih.gov/mapview/).
Mixed data have been reported with respect to the position of one marker (D3Rat63) employed in the present study. The Rat Genome Database (http://rgd.mcw.edu/objectSearch/ sslpReport.jsp?rgd_id ¼ 35218), the MIT rat genomics website (http://www.broad.mit.edu/rat/public/), and the NCBI website (http://www.ncbi.nlm.nih.gov/mapview/map_search.cgi?taxid
all list the marker as mapping to chromosome 3. The Ensembl website locates the marker on chromosome 8 but lists the map location on chromosome 3 (http://www.ensembl.org/Rattus_ norvegicus/markerview?marker ¼ oxsts6992). Analyzing with MAPMAKER/EXP and MAPMAKER/QTL (Remmers et al, 1996) and MapManager QT (Manly and Olson, 1999 ) the F2 genotype data that we generated, we found that by linkage analysis the D3Rat63 marker grouped with the chromosome 3 markers between D3Rat24 and D3Arb12. This mapping procedure confirms that the map location used for the D3Rat63 marker was correct. This procedure was followed for all markers used in the analyses to verify their orders and positions.
RESULTS
General characteristics of the F344 and LEW parental animals and F 2 intercross progeny used in the QTL analysis have been described previously (Brodkin et al, 1998) . F344 animals had significantly higher AIL, and higher Ga i1,2 and Ga i3 levels in the NAc, than did the LEW rats, although the ranges overlapped for the groups (Brodkin et al, 1998) . Serum levels of amphetamine did not differ for F344 and LEW rats (mean ± SEM for F344 (125 ± 10.8 ng/ml; n ¼ 10) and LEW (110±8.8 ng/ml; n ¼ 10); p ¼ 0.32), indicating that differences in AIL in F344 and LEW rats were not attributable to differences in amphetamine metabolism. No significant between-group differences in F344 and LEW rats were observed for NIL (Brodkin et al, 1998) . The F 2 progeny displayed AIL, Ga i1,2 , and Ga i3 levels intermediate between the F344 and LEW parental strains. Mean AIL scores in F 2 progeny were more similar to LEW than to F344 rats, whereas mean Ga i1,2 and Ga i3 levels were more similar to F344 rats than to LEW rats (Brodkin et al, 1998) . The distributions of the F 2 progeny selected for genotypic analysis are displayed in Figure 1 .
Results of an autosomal genomewide QTL linkage scan employing 178 markers are displayed in Table 1 . The broadest significance peak and largest likelihood (log ratio statistic (LRS)) score for AIL was observed on chromosome 3 (LRS max ¼ 21.3) between the markers D3Rat24 and D3Rat63 (Table 1 and Figure 2 ). This peak reached genomewide significance and was estimated to account for 12% of the phenotypic variance for AIL. QTL peaks in this region did not reach even 'suggestive' significance levels for NIL (LRS max ¼ 6.1; 4% of variance), Ga i1,2 levels (LRS max ¼ 9.8 (slightly more distal than AIL peak); 7% of variance), or Ga i3 levels (LRS max ¼ 3.1; 2% of variance). Peaks reaching 'suggestive' significance level thresholds for AIL were observed on the proximal region of chromosome 2 between D2Rat182 and D2Rat11 (LRS max ¼ 12.5; 8% of variance) and on chromosome 17 between D17Rat117 and D17Rat15 (LRS max ¼ 11.3; 7% of variance). w 2 statistics for adjacent loci reaching at least po0.05 significance for each individual locus are shown in Table 2 . No other peaks reached 'suggestive' significance.
Among the other phenotypes, the most robust QTL peak was observed for Ga i3 levels in the NAc. The QTL peak was significant at a genomewide level (LRS max ¼ 22.0; 15% of variance) and was located on the proximal end of chromosome 2 between D2Rat182 and D2Rat11. This region coincides with a 'suggestive' QTL peak for AIL. Within this region, no QTL peaks for NIL (LRS max ¼ 3.2; 2% of variance) nor for Ga i1,2 levels (LRS max ¼ 8.1; 5% of variance) reached 'suggestive' significance. No other QTL peaks for Ga i3 levels and none for NIL or Ga i1,2 reached genomewide significance. A 'suggestive' QTL peak for Ga i3 levels was observed in the vicinity of D9Rat126 (LRS max ¼ 11.5; 8% of variance), and 'suggestive' peaks for NIL (LRS max ¼ 10.3; 6% of variance) and Ga i1,2 level (LRS max ¼ 10.6; 7% of variance) were observed in the same region. An additional 'suggestive' peak for NIL was observed on chromosome 13 at D13Mit 4 (LRS max ¼ 12.2; 8% of variance).
CONCLUSIONS Summary of Findings
The current study investigated genomic contributions to differences in AIL, NIL, and levels of inhibitory G-protein subunits (Ga i1,2 and Ga i3 ) in the NAc in two inbred strains of rats. Our first hypothesis, that we would identify genomic regions contributing to AIL, NIL, Ga i1,2 levels, and Ga i3 levels, was partially supported. Specifically, QTLs reaching genomewide significance were identified for AIL and Ga i3 levels, and additional QTLs reaching 'suggestive' significance levels were identified for all four phenotypes. Our second hypothesis, that genomic regions contributing to AIL would be distinct from those contributing to NIL, was largely supported. No QTL for NIL reached 'suggestive' significance levels in the vicinities of QTLs reaching 'suggestive' or genomewide significance levels for AIL and vice versa. Our third hypothesis, that genomic regions contributing to AIL would partially overlap with those contributing to levels of Ga i1,2 and Ga i3 in the NAc, was QTLs influencing stimulant-induced locomotion and Ga i3 levels MN Potenza et al supported. Specifically, the location of the QTL peak on chromosome 2, which reached genomewide significance for Ga i3 levels in the NAc, coincided regionally with the QTL peak reaching 'suggestive' significance for AIL. Analogously, QTL peaks reaching 'suggestive' significance levels were observed in a similar region of chromosome 9 for NIL, Ga i1,2 levels, and Ga i3 levels. Together, these findings suggest that distinct genetic mechanisms underlie at least some of the differences in AIL and NIL observed in F344 and LEW rats. The findings also suggest overlapping genetic influences for biochemical and behavioral measures for AIL and Ga i3 levels and for NIL and Ga i1,2 and Ga i3 levels, respectively. The implications of these findings for psychiatric disorders are described below.
Importance of Current Findings
This study represents the first to our knowledge to identify via QTL analysis in any species genomic regions linked to inhibitory G-protein levels in the NAc, and to identify genomic regions associated with AIL and NIL in rats. Although QTL and other linkage analyses have been used in studies of numerous psychiatric disorders in humans and related phenotypes in animal models, few have addressed stimulant-related behaviors, and even fewer biochemical markers within the NAc, and we believe that ours is the first to do so simultaneously in any species. One prior study using recombinant inbred mice identified a region of chromosome 19 that influences DAT binding, which correlated with cocaine-and methamphetamine-induced locomotion (Janowsky et al, 2001) . Another study of recombinant inbred mice found a QTL associated with copper levels in NAc on a region of chromosomes 5 in males . Brain copper concentrations were associated with cocaine-related open-field behavior in these mice (Jones et al, 1999) . A third study found that mice lacking the M5 muscarinic receptor gene (located on chromosome 2) showed increased dopamine D2 receptor expression in the NAc and diminished AIL (Wang et al, 2004) . A fourth study used gene expression microarray analyses to identify differences in gene expression in the NAc in two mouse lines selected for differences in methamphetamine-induced locomotion (Palmer et al, 2005) . Using an internet database, the authors identified a region on chromosome 15 that co-mapped with the behavioral QTL for methamphetamine-induced locomotion. Similar regions of murine chromosome 15 have been associated with stimulant-, phencyclidine-, and ethanolinduced locomotion (Alexander et al, 1996; Grisel et al, 1997; Phillips et al, 1998; Jones et al, 1999; Boyle and Gill, 2001; Downing et al, 2003) . Together, these studies indicate that stimulant-induced locomotion is a poly-genetically determined behavior. With respect to the present findings, only chromosome 2 falls within a homologous region implicated in the current analysis, corresponding to the region of rat chromosome 3 with the most robust QTL for AIL.
Genomic Regions, Candidate Genes, and Implications
Our study, unlike any prior report, directly searched for QTLs associated with AIL using F2 progeny generated from an intercross of two rat strains showing parental differences in AIL. Consistent with prior studies, multiple genomic regions were identified in association with AIL. QTL analyses define relatively large intervals that are highly likely to contain multiple candidate genes that might contribute to the phenotype under investigation. Consequently, candidate genes within the region, while important to consider, should be viewed cautiously. The most robust QTL for AIL was found on chromosome 3 in a location corresponding to regions of chromosomes 11p, 15q, and 20q in humans and chromosome 2 in mice. Regions of human chromosome 11p have been identified in autosome/genome-wide scans as contributing to tobacco smoking, alcoholism, and opioid dependence (Long et al, 1998; Gelernter et al, 2004 Gelernter et al, , 2006 . The region of human chromosome 15 homologous to the identified region of rat chromosome 3 has been implicated in multiple studies of alcoholism and tobacco smoking and contains a GABA receptor gene cluster and the gene encoding the nicotinic acetylcholine a7 subunit (Leonard et al, 2000; Song et al, 2003) . The region of human chromosome 20q homologous to the identified region of rat chromosome 3 has been implicated in studies of cigarette traits (Saccone et al, 2003) . Other regions of the human genome map to the region of rat chromosome 3 containing the QTL. For example, the gene encoding brain-derived neurotrophic factor (BDNF), located on human chromosome 11p, is within the identified region of rat chromosome 3. BDNF is induced by chronic cocaine (Kumar et al, 2005) , regulated by CREB (Choi et al, 2006) , and implicated in cocaine withdrawal (Grimm et al, 2003; Pu et al, 2006) and cocaine-induced locomotion and reward (Horger et al, 1999; Hall et al, 2003) , and possibly associated with substance dependence (eg, Zhang et al, 2006) . Other candidate genes including the ones included within the identified region of rat chromosome 3 include those coding for the M5 muscarinic cholinergic receptor and DFosB/FosB. The muscarinic M5 receptor has been previously implicated in NAc function and AIL in mice (Wang et al, 2004) . DFosB has been widely implicated in addictive processes, including the rewarding and locomotor effects of stimulants (Nestler et al, 2001; Zhu et al, 2007) .
Among the genomic regions reaching suggestive significance for AIL, the one on chromosome 2 overlapped in proximity with the most robust QTL identified in the study, that for Ga i3 in the NAc. This region is homologous to regions of chromosome 5q in humans and chromosome 13 in mice. Although this region appears distinct from a GABA(A) gene cluster implicated in alcoholism (Radel et al, 2005) , regions of human chromosome 5q closer to the homologous region of rat chromosome have been implicated in alcohol craving (Ehlers and Wilhelmsen, 2005) and event-related brain potentials in families with a history of alcoholism (Almasy et al, 2001) . One of the genes in this region of rat chromosome 2 is that encoding the serotonin 1A receptor, which is expressed in the NAc (Luna-Munguia et al, 2005) , couples through Ga i with strongest affinity for Ga i3 (Pucadyil et al, 2005) , influences cocaine-induced dopamine levels in the NAc (Andrews et al, 2005) and cocaine-induced locomotion (Carey et al, 2005) , and has been implicated in aggressive behaviors, including those induced by cocaine (Knyshevski et al, 2005) . A nearby gene is that for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis, which has been implicated in cocaine self-administration (Self et al, 2004) . Also in this genomic region is the gene for the peptide CART (cocaine and amphetamine related transcript), which has been implicated in addictive processes including cocaine dependence (Jaworski and Jones, 2006) . CART is expressed in mesolimbic regions including the NAc (Philpot and Smith, 2006) , is regulated by stimulant exposure, dopaminergic transmission, and the cAMP pathway in the NAc (Hunter et al, 2006; Jones and Kuhar, 2006) , influences cocaine-induced locomotion (Jaworski et al, 2003) , and is elevated in the NAc of people who cocaine abusers (Albertson et al, 2004) .
A region of chromosome 17 corresponding to areas of chromosome 6p in humans and chromosome 13 in mice reached suggestive significance for AIL. In humans, chromosome 6p has been implicated in tobacco smoking (Fust et al, 2004) and intelligence in individuals with alcoholism and their families (Dick et al, 2006) . Of several genes in this region of rat chromosome 17, prolactin has been implicated in multiple studies of people with cocaine dependence. Prolactin levels have been associated with severity of cocaine use (Patkar et al, 2006a, b) , cocaine administration increases prolactin levels (Elman and Lukas, 2005) , serotonergically induced prolactin release is blunted in cocaine-dependent subjects (Patkar et al, 2006a, b) , and this effect is associated with high behavioral disinhibition and aggression (Patkar et al, 2006a, b) . Another gene in this vicinity is that encoding protein phosphatase 1, which has been implicated in the function of NAc neurons and in their response to cocaine (Hu et al, 2005; Svenningsson et al, 2005; Zachariou et al, 2006) . Also present is the gene for Cdk5, a protein kinase that has been implicated in cocainemediated dopamine signaling (Chergui et al, 2004; Takahashi et al, 2005) , is increased following chronic cocaine or methamphetamine exposure (Bibb et al, 2001; Benavides and Bibb, 2004; Chen and Chen, 2005) , interacts with tyrosine hydroxylase (Kansy et al, 2004) , is regulated by DFosB (Kumar et al, 2005) , and has been implicated in NAcmediated methamphetamine-induced locomotion (Chen and Chen, 2005) .
Dopamine systems contribute to exploratory behaviors in rodents (Kliethermes and Crabbe, 2006) , and differences in the genetic influences that contribute to exploratory and drug-induced locomotion have been reported (Hiroi and Agatsuma, 2005; Agatsuma et al, 2006) . A region of chromosome 9 contained suggestive QTL for NIL and levels of Ga i1,2 and Ga i3 in the NAc. This region corresponds to areas of chromosome 2q in humans and chromosome 1 in mice. In humans, a similar genomic region of chromosome 2q has been implicated in cooccurring alcoholism and depression (Nurnberger et al, 2001) . Among genes in this region of rat chromosome 9 is that for CREB, which is widely implicated in G-protein-related signal transduction in the NAc and animal models of stress and addiction (Barrot et al, 2005; Carlezon et al, 2005; Green et al, 2006; Nestler and Carlezon, 2006) .
Study Limitations and Future Directions
There exist multiple limitations in the present study. First, we examined only males, and future research in female populations is needed. Second, other inbred rat strains may also show differences in AIL, NIL, and levels of G a subunits in NAc, and in their relationship to other specific behavioral or biochemical measures of psychiatric relevance; we cannot draw any direct conclusions on these other strains at this point. However, although certain QTLs may be strain-specific, we speculate that common QTLs will influence phenotypes across strains and outbred rats. Also, it is likely that other strains may be used to identify additional QTLs relevant to stimulant responsiveness and biochemical measures in the NAc. A third limitation is that the findings were obtained in rats and the extent to which they are applicable to humans warrants further investigation. A fourth limitation is inherent to QTL analyses like the one employed here. Specifically, large genomic regions are identified that contain many candidate genes. Additional research is necessary to determine the extent to which specific genes are implicated and to identify the nature of genetic differences generating the biochemical and behavioral differences observed in the parental rat strains. Such work could involve gene expression investigations or the identification of strain-related differences in coding regions of candidate genes within the regions defined by the QTLs. A fifth limitation involves the use of an F2 design with respect to the investigation of dominant vs recessive loci or loci with effects dependent on interactions with strainspecific alleles at the X-chromosome or maternal environment. A sixth limitation involves the complex nature of behavioral responses like AIL and NIL, and future investigations could examine the extent to which specific genetic factors contribute to specific aspects (eg, the temporal magnitudes) of the responses.
Despite the limitations of the present study, the findings identify rat QTLs underlying differences in stimulant responsiveness and NAc functioning. As such, the investigation is important in several ways. Few prior studies have attempted to map neurochemical QTLs in inbred strains of rats. Since much work has been devoted to defining the neurochemistry in rat models of psychiatric disorders, this line of research is important in that it circumvents the need to translate phenotypes well described in rats to genetic models in mice. As rat genomics become increasingly well defined and more frequently used, this line of research will become increasingly important. Likewise, few prior studies have simultaneously mapped behavioral and neurochemical QTLs concurrently. The simultaneous assessment of QTLs provides an insight into the molecular mechanisms underlying behaviors with psychiatric relevance. Finally, and most importantly, the findings of specific genomic regions influencing stimulant responsiveness provide a basis for future investigations into the genetic basis for multiple psychiatric conditions in humans.
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